Company / Assets per Share
CytomX Therapeutics, Inc. Assets per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Assets per Share
$1.10
FY2025
5-year range
$1.10 / $5.19
FY2021-FY2025
Trend
-27.0%
vs FY2024
Sector context
#196 of 210
Health Care
What the data says
Among 210 Health Care companies, CytomX Therapeutics, Inc. is in the bottom 7% for assets per share. Assets per Share has declined for 5 consecutive years, from $7.88 in FY2020 to $1.10 in FY2025.
Based on SEC 10-K filings.
1.10 in FY2025 with a 5-year CAGR of -32.6%.
Declined from $3.00 to $1.10 over the past 2 years.
Health Care sector context is included.
Assets per Share over time
Growth rates
- 3-Year CAGR
- -34.7%
- 5-Year CAGR
- -32.6%
- 10-Year CAGR
- -
Sector benchmark
Bottom 7% in Health CareTop 93% of 210This company $1.10 Sector average $353.15
▼
-99.7% below sector average
Key checks
Key Insights
- CytomX Therapeutics, Inc.'s assets per share has declined for 5 consecutive years.
- In FY2025, assets per share decreased 27.0% year-over-year.
- Ranks #196 out of 210 companies in the Health Care sector.
- Peak assets per share was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -2.68 (distress zone, below 1.8 threshold)
- Strong profit margin: 23.1%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Assets per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $1.10 | -27.0% |
| FY2024 | $1.50 | -49.8% |
| FY2023 | $3.00 | -23.9% |
| FY2022 | $3.94 | -24.1% |
| FY2021 | $5.19 | -34.1% |
| FY2020 | $7.88 | +5.1% |
| FY2019 | $7.50 | -26.1% |
| FY2018 | $10.14 | -1.9% |
| FY2017 | $10.33 | +89.4% |
| FY2016 | $5.46 | -97.2% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026